Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations

Agatheeswaran Subramaniam; Carl Sandén; Larissa Moura-Castro; Kristijonas Žemaitis; Ludwig Schmiderer; Aurelie Baudet; Alexandra Bäckström; Elin Arvidsson; Simon Hultmark; Natsumi Miharada; Mattias Magnusson; Kajsa Paulsson; Thoas Fioretos; Jonas Larsson

doi:10.3324/haematol.2021.280303

Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations

Haematologica. 2022 Sep 1;107(9):2271-2275. doi: 10.3324/haematol.2021.280303.

Affiliations

¹ Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund. agatheeswaran.subramaniam@med.lu.se.
² Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund.
³ Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund.
⁴ Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund. jonas.larsson@med.lu.se.

No abstract available

MeSH terms

Cell Cycle Proteins / genetics
Humans
Leukemia, Myeloid, Acute* / genetics
Mutation
Synthetic Lethal Mutations*

Substances

Cell Cycle Proteins
STAG2 protein, human

Grants and funding

Funding: This work was funded to JL by grants from the Swedish Research Council, the Swedish Cancer Foundation, the Swedish Pediatric Cancer Foundation, Knut och Alice Wallenbergs Stiftelse and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 648894). AS was supported from the Swedish Cancer Foundation, Royal Physiographic Society of Lund and Lady TATA memorial trust. The work was further supported by the HematoLinné and StemTherapy programs at Lund University.